Allen Dick
Known title: DirectorCIK: 0001582779
Allen Dick's purchase track record
Allen Dick has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/27/2023 | TNDM | $95K | +48.2% | +171.7% | +16.6% |
| 5/18/2023 | TNDM | $295K | -2.8% | -37.9% | +7.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| TNDM | ▼ Sell | Gift | 1,000 | $20K | 6/2/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| TNDM | ▼ Sell | Gift | 6,639 | $258K | 8/7/2024 | View on chart |
| TNDM | ▼ Sell | Other | 9,396 | $0 | 6/11/2024 | View on chart |
| TNDM | ▼ Sell | Other | 9,396 | $0 | 6/11/2024 | View on chart |
| TNDM | ▼ Sell | Gift | 1,892 | $97K | 6/6/2024 | View on chart |
| TNDM | ▼ Sell | Open Market | 5,000 | $258K | 5/30/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Open Market | 5,000 | $95K | 11/27/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▼ Sell | Gift | 1,000 | $29K | 5/22/2023 | View on chart |
| TNDM | ▲ Buy | Open Market | 10,000 | $295K | 5/18/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,205 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.